在血友病B中经过PK引导过渡到延长半衰期的因子IX后,药理动力学,出血控制和成本分析的改善:一项多中心研究
Maria Chovi-Trull1, Juan Eduardo Megías-Vericat1, Tomás Palanques-Pastor1
1Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Thrombosis research
|January 13, 2026
概括
切换到延长半衰期的XIX因子缩剂 (FIX-EHL) 显著改善了B型血友病患者的药理动力学参数和降低了出血率. 虽然输液频率和剂量下降,但转换并没有降低整体治疗成本.
科学领域:
- 血液学 血液学 血液学
- 药理动力学 药理动力学
- 药物经济学 药物经济学
背景情况:
- 延长半衰期的XIX因子缩剂 (FIX-EHL) 为血友病B (HB) 患者提供了改善的临床结果和减少的治疗负担.
- 标准半衰期因子IX缩剂 (FIX-SHL) 是一种常见的HB治疗方法,但需要频繁输注.
研究的目的:
- 在从FIX-SHL切换到FIX-EHL后,分析药理动力学 (PK) 和临床参数的变化,用于预防重度/中度HB患者.
- 评估PK导向切换对出血率,FIX消耗和治疗成本的影响.
主要方法:
- 一项多中心,比较,观察性研究分析了21名HB患者从FIX-SHL切换到FIX-EHL.
- 通过使用WAPPS-Hemo®计算了PK参数 (t1/2,AUC).
- 每年出血率 (ABR),关节出血,FIX消费,输液频率和成本都记录在切换前后.
主要成果:
- 观察到PK参数的显著改善,t1/2和AUC的中位改善比分分别为4.1和4.2.
- 观察到ABR的统计显著降低,6名目标关节患者中有5名患者实现了解决.
- 输液频率和每周FIX剂量分别下降了50.0%和56.3%,但每名患者的年度成本增加了28,254.9欧元.
结论:
- 从FIX-SHL到FIX-EHL的PK导向切换改善了PK参数,并显著降低了HB患者的出血率.
- 切换导致每周剂量和输液频率降低,但不会节省成本.
- FIX-EHL代表了管理血友病B的有价值的治疗选择,尽管成本增加,但提高了患者的治疗结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Dosage Regimens: Partial Pharmacokinetic Parameters
148
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
148
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Biopharmaceutical Factors Influencing Drug Product Design: Overview
232
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
232
Measurement of Bioavailability: Pharmacodynamic Methods
230
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
230


